Prestige Consumer Healthcare (PBH) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $49.92, +1.46% vs the prior close of $49.20.
- Volume 580.66K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PBH rises 1.5% to $49.92, a 1-month high. Closed at $49.92, +1.46% vs the prior close of $49.20. Day range $49.28–$50.27, opened at $49.48.
PBH daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — PBH rises 1.5% to $49.92, a 1-month high
- Closed at $49.92, +1.46% vs the prior close of $49.20. Day range $49.28–$50.27, opened at $49.48.
- Volume was 580.66K shares, 1.0x its 50-day average of 554.68K.
- Price is +1.5% vs its 50-day average ($49.21) and -9.0% vs its 200-day average ($54.83).
- 52-week range $42.62–$71.07; today's close sits at 26% of that range, 29.8% below the 52-week high.
Oct 15, 2026 — PBH rises 1.7% to $49.20, a 1-month high
- Closed at $49.20, +1.65% vs the prior close of $48.40. Day range $48.83–$50.84, opened at $49.41.
- Volume was 533.90K shares, 1.0x its 50-day average of 556.21K.
- Price is -0.2% vs its 50-day average ($49.30) and -10.4% vs its 200-day average ($54.89).
- 52-week range $42.62–$71.07; today's close sits at 23% of that range, 30.8% below the 52-week high.
Oct 14, 2026 — PBH ends flat (-0.2%) to $48.40
- Closed at $48.40, -0.21% vs the prior close of $48.50. Day range $47.85–$49.15, opened at $48.70.
- Volume was 684.00K shares, 1.2x its 50-day average of 563.97K.
- Price is -2.0% vs its 50-day average ($49.37) and -11.9% vs its 200-day average ($54.96).
- 52-week range $42.62–$71.07; today's close sits at 20% of that range, 31.9% below the 52-week high.
Oct 13, 2026 — PBH dips 1.0% to $48.50
- Closed at $48.50, -1.02% vs the prior close of $49.00. Day range $48.45–$49.78, opened at $49.52.
- Volume was 494.70K shares, 0.9x its 50-day average of 570.73K.
- Price is -1.9% vs its 50-day average ($49.44) and -11.9% vs its 200-day average ($55.04).
- 52-week range $42.62–$71.07; today's close sits at 21% of that range, 31.8% below the 52-week high.
Oct 12, 2026 — PBH rises 1.6% to $49.00, a 1-month high, 7 up days in a row
- Closed at $49.00, +1.60% vs the prior close of $48.23. Day range $47.80–$49.41, opened at $48.52.
- Volume was 416.40K shares, 0.7x its 50-day average of 570.26K.
- Price is -1.0% vs its 50-day average ($49.51) and -11.1% vs its 200-day average ($55.11).
- 52-week range $42.62–$71.07; today's close sits at 22% of that range, 31.1% below the 52-week high.
- That makes 7 straight gains.
Oct 9, 2026 — PBH rises 0.8% to $48.23, a 1-month high, 6 up days in a row
- Closed at $48.23, +0.75% vs the prior close of $47.87. Day range $47.48–$48.73, opened at $47.80.
- Volume was 323.70K shares, 0.6x its 50-day average of 571.63K — lighter than usual.
- Price is -2.6% vs its 50-day average ($49.54) and -12.6% vs its 200-day average ($55.17).
- 52-week range $42.62–$71.07; today's close sits at 20% of that range, 32.1% below the 52-week high.
- That makes 6 straight gains.
Oct 8, 2026 — PBH rises 0.6% to $47.87, 5 up days in a row
- Closed at $47.87, +0.63% vs the prior close of $47.57. Day range $46.74–$47.94, opened at $47.62.
- Volume was 558.50K shares, 1.0x its 50-day average of 568.19K.
- Price is -3.4% vs its 50-day average ($49.57) and -13.4% vs its 200-day average ($55.25).
- 52-week range $42.62–$71.07; today's close sits at 18% of that range, 32.6% below the 52-week high.
- That makes 5 straight gains.
Oct 7, 2026 — PBH rises 2.4% to $47.57, 4 up days in a row
- Closed at $47.57, +2.43% vs the prior close of $46.44. Day range $46.34–$47.72, opened at $46.57.
- Volume was 460.90K shares, 0.8x its 50-day average of 567.76K.
- Price is -4.2% vs its 50-day average ($49.66) and -14.0% vs its 200-day average ($55.31).
- 52-week range $42.62–$71.07; today's close sits at 17% of that range, 33.1% below the 52-week high.
- That makes 4 straight gains.
Oct 6, 2026 — PBH rises 1.8% to $46.44, 3 up days in a row
- Closed at $46.44, +1.84% vs the prior close of $45.60. Day range $45.58–$46.61, opened at $45.90.
- Volume was 660.90K shares, 1.2x its 50-day average of 563.26K.
- Price is -6.6% vs its 50-day average ($49.74) and -16.2% vs its 200-day average ($55.39).
- 52-week range $42.62–$71.07; today's close sits at 13% of that range, 34.7% below the 52-week high.
- That makes 3 straight gains.
Oct 5, 2026 — PBH rises 0.8% to $45.60
- Closed at $45.60, +0.75% vs the prior close of $45.26. Day range $44.77–$45.88, opened at $45.11.
- Volume was 604.40K shares, 1.1x its 50-day average of 558.18K.
- Price is -8.5% vs its 50-day average ($49.82) and -17.8% vs its 200-day average ($55.47).
- 52-week range $42.62–$71.07; today's close sits at 10% of that range, 35.8% below the 52-week high.
Oct 2, 2026 — PBH rises 1.1% to $45.26
- Closed at $45.26, +1.09% vs the prior close of $44.77. Day range $44.60–$45.75, opened at $44.88.
- Volume was 534.80K shares, 1.0x its 50-day average of 558.34K.
- Price is -9.3% vs its 50-day average ($49.90) and -18.5% vs its 200-day average ($55.55).
- 52-week range $42.62–$71.07; today's close sits at 9% of that range, 36.3% below the 52-week high.
PBH latest news & SEC filings
Every SEC filing by or about PBH in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $265.71M (prior year $249.53M) (+6.5% vs Jun 30, 2025)
- Net income: $29.18M (prior year $47.47M) (-38.5% vs Jun 30, 2025)
- Diluted EPS: $0.61 (prior year $0.95) (-35.8% vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
Jul 9, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Exhibits / financial statements only (Item 9.01).
Jul 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jun 30, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Exhibits / financial statements only (Item 9.01).
Jun 29, 2026 · Form ARS — Annual report to shareholders
Annual report to shareholders
Jun 29, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Things to know before you trade PBH
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Feb 5, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.57% (largest 4.1%).
- Liquidity: about 563.25K shares (≈$28.12M) trade per day on average.
- 52-week position: $49.92 vs a range of $42.62–$71.07 (26% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Jeffrey Zerillo sold 351 shares on May 11, 2026.
- Latest filings: 8-K Aug 14, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 47.37M shares outstanding (Jul 31, 2026), -3.7% vs a year earlier — the company has been reducing its share count.
- Listing: NYSE · industry: Pharmaceutical Preparations.
PBH market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 49.48 | 50.27 | 49.28 | 49.92 | 580.66K |
| Oct 15, 2026 | 49.41 | 50.84 | 48.83 | 49.20 | 533.90K |
| Oct 14, 2026 | 48.70 | 49.15 | 47.85 | 48.40 | 684.00K |
| Oct 13, 2026 | 49.52 | 49.78 | 48.45 | 48.50 | 494.70K |
| Oct 12, 2026 | 48.52 | 49.41 | 47.80 | 49.00 | 416.40K |
| Oct 9, 2026 | 47.80 | 48.73 | 47.48 | 48.23 | 323.70K |
| Oct 8, 2026 | 47.62 | 47.94 | 46.74 | 47.87 | 558.50K |
| Oct 7, 2026 | 46.57 | 47.72 | 46.34 | 47.57 | 460.90K |
| Oct 6, 2026 | 45.90 | 46.61 | 45.58 | 46.44 | 660.90K |
| Oct 5, 2026 | 45.11 | 45.88 | 44.77 | 45.60 | 604.40K |
| Oct 2, 2026 | 44.88 | 45.75 | 44.60 | 45.26 | 534.80K |
| Oct 1, 2026 | 45.76 | 46.13 | 44.64 | 44.77 | 731.40K |
| Sep 30, 2026 | 46.69 | 46.69 | 45.85 | 45.87 | 583.50K |
| Sep 29, 2026 | 46.73 | 46.85 | 46.04 | 46.74 | 566.70K |
| Sep 28, 2026 | 46.25 | 47.33 | 46.24 | 46.93 | 651.80K |
| Sep 25, 2026 | 45.34 | 46.72 | 44.97 | 46.61 | 467.70K |
| Sep 24, 2026 | 46.12 | 46.49 | 45.30 | 45.65 | 627.20K |
| Sep 23, 2026 | 47.45 | 47.46 | 45.91 | 45.92 | 503.90K |
| Sep 22, 2026 | 47.55 | 47.80 | 47.02 | 47.73 | 619.60K |
| Sep 21, 2026 | 45.01 | 47.00 | 44.46 | 46.80 | 660.40K |
About Prestige Consumer Healthcare
Prestige Consumer Healthcare (PBH) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in TARRYTOWN, NY. Fiscal year ends March 31. SEC CIK 1295947.
PBH board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| John E Byom | Director | Aug 5, 2026 |
| Celeste A. Clark | Director | Aug 5, 2026 |
| James Darecca | Director | Aug 5, 2026 |
| John F. Kelly | Director | Aug 5, 2026 |
| Ronald M. Lombardi | Chief Executive Officer | May 11, 2026 |
| Dawn M. Zier | Director | Aug 5, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Ronald M. Lombardi | Chief Executive Officer | May 11, 2026 |
| Adel Mekhail | EVP, Marketing & Sales | May 11, 2026 |
| William P'Pool | See Remarks | May 6, 2026 |
| Jose Luis Rosado | See Remarks | Jan 29, 2026 |
| Christine Sacco | CFO & COO | May 14, 2026 |
| Jeffrey Zerillo | Senior VP Operations | May 12, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 11, 2026 | Jeffrey Zerillo | Sale | 351 | $52.28 |
| May 11, 2026 | Jeffrey Zerillo | Sale | 351 | $52.28 |
| May 11, 2026 | Jeffrey Zerillo | Sale | 351 | $52.28 |
| May 11, 2026 | Jeffrey Zerillo | Sale | 351 | $52.28 |
| May 7, 2026 | Jeffrey Zerillo | Sale | 305 | $54.36 |
| May 7, 2026 | Jeffrey Zerillo | Sale | 305 | $54.36 |
| May 7, 2026 | Jeffrey Zerillo | Sale | 305 | $54.36 |
| May 7, 2026 | Jeffrey Zerillo | Sale | 305 | $54.36 |
| May 5, 2026 | Jeffrey Zerillo | Sale | 1,207 | $54.99 |
| May 5, 2026 | Jeffrey Zerillo | Sale | 1,207 | $54.99 |
| May 5, 2026 | Jeffrey Zerillo | Sale | 1,207 | $54.99 |
| May 5, 2026 | Jeffrey Zerillo | Sale | 1,207 | $54.99 |
| May 5, 2026 | Jeffrey Zerillo | Sale | 346 | $55.32 |
| May 5, 2026 | Jeffrey Zerillo | Sale | 346 | $55.32 |
| May 5, 2026 | Jeffrey Zerillo | Sale | 346 | $55.32 |
PBH financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Mar 31, 2026 | $1.09B | $190.30M | 3.91 | $257.63M |
| Mar 31, 2025 | $1.14B | $214.60M | 4.29 | $251.51M |
| Mar 31, 2024 | $1.13B | $209.34M | 4.17 | $248.93M |
| Mar 31, 2023 | $1.13B | $-82.31M | -1.65 | $229.72M |
| Mar 31, 2022 | $1.09B | $205.38M | 4.04 | $259.92M |
Latest balance sheet: total assets $4.57B, total liabilities $2.65B, cash $89.13M (as of Jun 30, 2026).
PBH earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $54.43 |
| May 13, 2026 | 8-K Item 2.02 (results) | $51.81 |
| Feb 5, 2026 | 8-K Item 2.02 (results) | $65.55 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $61.36 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $67.61 |
| May 8, 2025 | 8-K Item 2.02 (results) | $87.04 |
| Feb 6, 2025 | 8-K Item 2.02 (results) | $87.35 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $80.09 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Feb 8, 2024 | 8-K Item 2.02 (results) | — |
| Nov 2, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on PBH
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.